Getty ImagesRelated
Motilal Oswal has buy call on Jubilant Pharmova Ltd. with a target price of Rs 920. The current market price of Jubilant Pharmova Ltd. is Rs 718.15. Time period given by analyst is one year when Jubilant Pharmova Ltd. price can reach defined target.
Jubilant Pharmova Ltd., incorporated in the year 1978, is a Mid Cap company (having a market cap of Rs 11241.27 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Consolidated Total Income of Rs 1586.47 Crore, down -10.62 % from last quarter Total Income of Rs 1774.93 Crore and down -34.19 % from last year same quarter Total Income of Rs 2410.85 Crore. Company reported net profit after tax of Rs 199.30 Crore in latest quarter.
Investment Rationale
The brokerage has tweaked estimates for FY22/FY23E to reflect the impact of the Import Alert at the Roorkee plant. The brokerage expects an 11% CAGR in Radiopharma sales and 8% CAGR in CDMO (adjusted for one-time sales of COVID products in FY21) over FY21–23. Thus, it expects a 10% earnings CAGR over FY21–23. It maintains BUY on the stock, with TP of INR920 (valued at 9x 12M forward EV/EBITDA).
Promoter/FII Holdings
Promoters held 50.7 per cent stake in the company as of March 31, 2021, while FIIs held 25.8 per cent, DIIs 1.3 and public and others 22.3 per cent.
Jubilant Pharmova Ltd., incorporated in the year 1978, is a Mid Cap company (having a market cap of Rs 11241.27 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Consolidated Total Income of Rs 1586.47 Crore, down -10.62 % from last quarter Total Income of Rs 1774.93 Crore and down -34.19 % from last year same quarter Total Income of Rs 2410.85 Crore. Company reported net profit after tax of Rs 199.30 Crore in latest quarter.
Investment Rationale
The brokerage has tweaked estimates for FY22/FY23E to reflect the impact of the Import Alert at the Roorkee plant. The brokerage expects an 11% CAGR in Radiopharma sales and 8% CAGR in CDMO (adjusted for one-time sales of COVID products in FY21) over FY21–23. Thus, it expects a 10% earnings CAGR over FY21–23. It maintains BUY on the stock, with TP of INR920 (valued at 9x 12M forward EV/EBITDA).
Promoter/FII Holdings
Promoters held 50.7 per cent stake in the company as of March 31, 2021, while FIIs held 25.8 per cent, DIIs 1.3 and public and others 22.3 per cent.
(Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
